RU2498811C1 - Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей - Google Patents
Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей Download PDFInfo
- Publication number
- RU2498811C1 RU2498811C1 RU2012115653/15A RU2012115653A RU2498811C1 RU 2498811 C1 RU2498811 C1 RU 2498811C1 RU 2012115653/15 A RU2012115653/15 A RU 2012115653/15A RU 2012115653 A RU2012115653 A RU 2012115653A RU 2498811 C1 RU2498811 C1 RU 2498811C1
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- osteoporosis
- prevention
- bone fractures
- vitamin
- Prior art date
Links
- 208000010392 Bone Fractures Diseases 0.000 title claims abstract description 12
- 230000002265 prevention Effects 0.000 title claims abstract description 12
- 208000001164 Osteoporotic Fractures Diseases 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 229940088594 vitamin Drugs 0.000 claims abstract description 25
- 229930003231 vitamin Natural products 0.000 claims abstract description 25
- 235000013343 vitamin Nutrition 0.000 claims abstract description 25
- 239000011782 vitamin Substances 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 24
- 244000144987 brood Species 0.000 claims abstract description 23
- 239000002207 metabolite Substances 0.000 claims abstract description 13
- 229940043430 calcium compound Drugs 0.000 claims abstract description 12
- 150000001674 calcium compounds Chemical class 0.000 claims abstract description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims description 21
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 14
- 229930003316 Vitamin D Chemical group 0.000 claims description 12
- 235000019166 vitamin D Nutrition 0.000 claims description 12
- 239000011710 vitamin D Chemical group 0.000 claims description 12
- 150000003710 vitamin D derivatives Chemical group 0.000 claims description 12
- 229940046008 vitamin d Drugs 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 abstract description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 6
- 239000011707 mineral Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 239000003098 androgen Substances 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 230000037182 bone density Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000005755 formation reaction Methods 0.000 description 27
- 208000001132 Osteoporosis Diseases 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 15
- 229910052791 calcium Inorganic materials 0.000 description 15
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000033558 biomineral tissue development Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 3
- 239000001354 calcium citrate Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 235000013337 tricalcium citrate Nutrition 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- -1 videchol Chemical compound 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012115653/15A RU2498811C1 (ru) | 2012-04-19 | 2012-04-19 | Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей |
| CA2870828A CA2870828C (en) | 2012-04-19 | 2012-08-21 | A method for preventing and treating osteoporosis and bone fractures and a preparation for preventing and treating osteoporosis and bone fractures |
| UAA201412409A UA111280C2 (uk) | 2012-04-19 | 2012-08-21 | Препарат та спосіб для профілактики і лікування остеопорозу та переломів кісток |
| EA201401157A EA026534B1 (ru) | 2012-04-19 | 2012-08-21 | Препарат и способ профилактики и лечения остеопороза и переломов костей |
| JP2015506935A JP6286418B2 (ja) | 2012-04-19 | 2012-08-21 | 骨粗鬆症もしくは骨折の予防または治療剤 |
| EP12874726.8A EP2875820A4 (en) | 2012-04-19 | 2012-08-21 | COMPOSITION AND METHOD FOR PROPHYLAXIS AND TREATMENT OF OSTEOPOROSIS AND BONE BREAKS |
| AU2012377478A AU2012377478B2 (en) | 2012-04-19 | 2012-08-21 | Preparation and method for the prophylaxis and treatment of osteoporosis and bone fractures |
| PCT/RU2012/000689 WO2013157984A1 (ru) | 2012-04-19 | 2012-08-21 | Препарат и способ профилактики и лечения остеопороза и переломов костей |
| CN201280074010.9A CN104379154A (zh) | 2012-04-19 | 2012-08-21 | 骨折和骨质疏松防治方法和药物 |
| BR112014025973-9A BR112014025973B1 (pt) | 2012-04-19 | 2012-08-21 | Preparação e método para prevenir e tratar a osteoporose e fraturas ósseas |
| US14/395,482 US20150174176A1 (en) | 2012-04-19 | 2012-08-21 | Preparation and method for the prophylaxis and treatment of osteoporosis and bone fractures |
| IL235171A IL235171B (en) | 2012-04-19 | 2014-10-19 | A method for preventing and treating osteoporosis and bone fractures and a preparation for preventing and treating osteoporosis and bone fractures |
| IN9779DEN2014 IN2014DN09779A (cg-RX-API-DMAC10.html) | 2012-04-19 | 2014-11-19 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012115653/15A RU2498811C1 (ru) | 2012-04-19 | 2012-04-19 | Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2498811C1 true RU2498811C1 (ru) | 2013-11-20 |
Family
ID=49383802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012115653/15A RU2498811C1 (ru) | 2012-04-19 | 2012-04-19 | Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей |
Country Status (13)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2593018C1 (ru) * | 2015-10-28 | 2016-07-27 | Общество С Ограниченной Ответственностью "Парафарм" | Способ лечения остеоартроза |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2548776C2 (ru) * | 2013-01-11 | 2015-04-20 | Общество С Ограниченной Ответственностью "Парафарм" | Способ и препарат для ускорения консолидации переломов костей |
| RU2549461C2 (ru) * | 2013-01-11 | 2015-04-27 | Общество С Ограниченной Ответственностью "Парафарм" | Способ и препарат для лечения артритов и артрозов |
| RU2564111C9 (ru) * | 2013-07-03 | 2016-03-20 | Общество С Ограниченной Ответственностью "Парафарм" | Применение адсорбированного гомогената трутневого расплода и витаминов группы d и/или их активных метаболитов для профилактики и лечения острых респираторных заболеваний и гриппа |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2412616C1 (ru) * | 2009-11-30 | 2011-02-27 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище для профилактики заболеваний остеопорозом |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743596A (en) * | 1987-06-16 | 1988-05-10 | Lapin Alfred R | Anti-arthritic preparation |
| CN1101684C (zh) * | 1997-07-24 | 2003-02-19 | 薛大权 | 蜂蛹钙制剂 |
| AU2001278744A1 (en) * | 2000-08-17 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Remedial agent for osteoporosis |
| CA2526845A1 (en) * | 2003-06-06 | 2005-03-31 | Wyeth | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby |
| AU2009214052B2 (en) * | 2008-02-13 | 2015-05-07 | Dsm Ip Assets B.V. | Combined use of 25-hydroxy-vitamin D3 and vitamin D3 for improving bone mineral density and for treating osteoporosis |
| FR2945748A1 (fr) * | 2009-05-20 | 2010-11-26 | Debregeas Et Associes Pharma | Medicament a base de calcium et de vitamine d. |
| RU2466732C1 (ru) * | 2011-05-31 | 2012-11-20 | Общество С Ограниченной Ответственностью "Парафарм" | Способ заполнения полостных образований в метафизарных (трабекулярных) участках костей кальцием и предотвращения выведения из них кальция |
| RU2497533C1 (ru) * | 2012-04-19 | 2013-11-10 | Общество С Ограниченной Ответственностью "Парафарм" | Способ и препарат для профилактики и лечения атипичного остеопороза с нормальной или повышенной минерализацией костной ткани с наличием полостных образований в трабекулярных отделах костей (и ему близких состояниях при избыточной массе и метаболическом синдроме) |
-
2012
- 2012-04-19 RU RU2012115653/15A patent/RU2498811C1/ru active
- 2012-08-21 EP EP12874726.8A patent/EP2875820A4/en not_active Withdrawn
- 2012-08-21 UA UAA201412409A patent/UA111280C2/uk unknown
- 2012-08-21 JP JP2015506935A patent/JP6286418B2/ja not_active Expired - Fee Related
- 2012-08-21 AU AU2012377478A patent/AU2012377478B2/en not_active Ceased
- 2012-08-21 EA EA201401157A patent/EA026534B1/ru unknown
- 2012-08-21 WO PCT/RU2012/000689 patent/WO2013157984A1/ru not_active Ceased
- 2012-08-21 BR BR112014025973-9A patent/BR112014025973B1/pt active IP Right Grant
- 2012-08-21 US US14/395,482 patent/US20150174176A1/en active Pending
- 2012-08-21 CN CN201280074010.9A patent/CN104379154A/zh active Pending
- 2012-08-21 CA CA2870828A patent/CA2870828C/en active Active
-
2014
- 2014-10-19 IL IL235171A patent/IL235171B/en active IP Right Grant
- 2014-11-19 IN IN9779DEN2014 patent/IN2014DN09779A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2412616C1 (ru) * | 2009-11-30 | 2011-02-27 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище для профилактики заболеваний остеопорозом |
Non-Patent Citations (1)
| Title |
|---|
| Кальций-Д 3 Никомед форте. Перечень данных [онлайн] 2006 [найдено 2012.12.17] - найдено в интернете: URL http://www.poisklekarstv.ru/lekcat/2533_kaltsiyd3-nikomed-forte.html. Кальций, витамин Д и его метаболиты в лечении остеопороза. Перечень данных [онлайн] 2010 [найдено 2012.12.24] - найдено в интернете: URL: http://www.scientificmedicine.ru/revmatolog/Kalcijj-vitamin-D, лист 1. Струков В.И. Факторы риска гиперминерализации // Актуальные проблемы анестезиологии, реаниматологии и скорой медицинской помощи: диагностика, интенсивная терапия и реабилитация. Пенза: 22 сентября 2011, с.214-217. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2593018C1 (ru) * | 2015-10-28 | 2016-07-27 | Общество С Ограниченной Ответственностью "Парафарм" | Способ лечения остеоартроза |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150174176A1 (en) | 2015-06-25 |
| IL235171A0 (en) | 2014-12-31 |
| EP2875820A4 (en) | 2016-01-27 |
| JP2015514755A (ja) | 2015-05-21 |
| JP6286418B2 (ja) | 2018-02-28 |
| IL235171B (en) | 2019-09-26 |
| IN2014DN09779A (cg-RX-API-DMAC10.html) | 2015-07-31 |
| UA111280C2 (uk) | 2016-04-11 |
| BR112014025973B1 (pt) | 2021-09-28 |
| CN104379154A (zh) | 2015-02-25 |
| EA026534B1 (ru) | 2017-04-28 |
| CA2870828C (en) | 2019-01-15 |
| EA201401157A1 (ru) | 2015-05-29 |
| CA2870828A1 (en) | 2013-10-24 |
| WO2013157984A1 (ru) | 2013-10-24 |
| AU2012377478B2 (en) | 2017-07-06 |
| AU2012377478A1 (en) | 2014-12-11 |
| BR112014025973A2 (pt) | 2017-06-27 |
| EP2875820A1 (en) | 2015-05-27 |
| AU2012377478A8 (en) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2728117T3 (es) | Complemento alimenticio biológicamente activo para la prevención de la osteoporosis | |
| RU2497533C1 (ru) | Способ и препарат для профилактики и лечения атипичного остеопороза с нормальной или повышенной минерализацией костной ткани с наличием полостных образований в трабекулярных отделах костей (и ему близких состояниях при избыточной массе и метаболическом синдроме) | |
| CN104001157B (zh) | 一种防治骨质疏松症的复方制剂及其制备方法 | |
| EA026534B1 (ru) | Препарат и способ профилактики и лечения остеопороза и переломов костей | |
| JP2015516974A5 (ja) | 骨の線維柱帯における空洞病巣発生を有する正常又は増加した骨組織石灰化に伴う非定型骨粗鬆症を対象にする予防または治療剤 | |
| Gupta et al. | Multiple Roles of Calcium in Maintaining Human Health | |
| BR112017007364B1 (pt) | Composições farmacêuticas e usos das mesmas para o tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes submetidos à cirurgia de bypass gástrico | |
| WO2012166003A1 (ru) | Способ заполнения кальцием полостных образований костей | |
| CN101991829B (zh) | 一种治疗胃病的药物 | |
| EA028560B1 (ru) | Способ и препарат для лечения артритов и артрозов | |
| Zujkina et al. | The pharmacotechnological studies of the phytospecies composition for the complex therapy of mastopathy | |
| RU2678976C1 (ru) | Способ профилактики длительного болевого синдрома в отдаленном послеоперационном периоде у пациентов с дисплазией соединительной ткани | |
| KR20250145022A (ko) | 다낭성 난소 증후군의 치료에서의 사용을 위한 조성물 | |
| RU2282445C1 (ru) | Способ коррекции вегетативных проявлений климактерического синдрома у женщин с ишемическими нарушениями мозгового кровообращения | |
| HK40127583A (en) | Composition for the use in the treatment of polycystic ovary syndrome | |
| RU2555351C1 (ru) | Способ лечения хронического описторхоза у больных с розацеа | |
| US20190381072A1 (en) | Preparation for the Prophylaxis and Treatment of Atypical Osteoporosis | |
| CN103766873A (zh) | 一种改善亚健康、抗衰老的组合物及其制剂 | |
| TW201625269A (zh) | 含有高溶性元素和維生素ｄ並能預防和改善補鈣期間的腸胃狀況的組合物 | |
| UA50462A (uk) | Спосіб профілактики ускладнень перебігу вагітності та пологів у жінок з аліментарно-конституційним ожирінням | |
| CN104173500A (zh) | 一种治疗吊线风的外用中药组合物及其制备方法和使用方法 | |
| CN104189214A (zh) | 一种治疗神经衰弱的配方 | |
| Ali et al. | RENAL PROFILE OF SPRAGUE-DAWLEY RATS FOLLOWING 6 MONTHS REPEATED ORAL ADMINISTRATION OF TUALANG HONEY: A PRELIMINARY OUTCOME |